CLGN Stock Analysis: Buy, Sell, or Hold?
CLGN - CollPlant Biotechnologies Ltd Ordinary Shares
$0.37
0.01 (3.02%)
▲
5d:
+1.39%
30d:
+9.28%
90d:
+13.35%
BUY
HIGH Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 19, 2026
Get Alerted When CLGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CLGN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: CLGN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: CLGN is currently trading at $0.36, which is considered slightly high relative to its 30-day fair value range of $0.33 to $0.37. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.0) compared to its historical average (3.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CLGN is in a strong downtrend. Immediate support is located at $0.30, while resistance sits at $0.43. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: CLGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.12 (+2946.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CLGN is in a strong downtrend. Immediate support is located at $0.30, while resistance sits at $0.43. The stock is showing strong short-term momentum, up 3.0% recently.
Market Sentiment: CLGN has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $11.12 (+2946.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.33 -
$0.37
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
85.7%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.0%)
- BULLISH: Trading 2946.6% below Wall St target ($11.12)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$0.33 -
$0.37
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$0.30
Resistance Level
$0.43
Current Trend
Strong Downtrend
Technical data as of
Jul 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.03
Wall Street Target
$11.12
(+2946.6%)
Revenue Growth (YoY)
-96.4%
PE vs Historical
-2.0 vs 3.5
CHEAP
Share & Embed Analysis
Last updated: July 15, 2026 12:46 AM ET
Data refreshes hourly during market hours. Next update: 1:46 AM
Data refreshes hourly during market hours. Next update: 1:46 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLGN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 64 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 55 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 59 HOLD |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 60 BUY |
